Obermatt
See Similar Stocks →

Dottikon

SWX:DESN · CH0582581713
PharmaceuticalsMedium

360

34
EV / EBIT25
Price / Owner Earnings11
Owner Earnings Yield27
Dividend Yield1
Price/Sales31
EV / Gross Profit12
Price/Book56
Return on Capital39
Cash Return on Capital21
Return on Equity41
EBIT Margin77
Gross Profitability13
Cash Conversion34
Accruals19
Owner Earnings Margin46
Sales growth94
Profit Growth58
Long-Term EPS Growth6
Owner Earnings Growth89
Reinvestment62
Price momentum44
Debt load71
Refinancing77
Debt Payback100
Liquidity86
Analyst ratings16
Opinion Changes50
Price Target Upside74
Market mood81
Value Creation14/20strong value creator
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Dottikon generates returns well above its cost of capital, the foundation of durable shareholder value.

Profile

CountrySwitzerland
IndustryPharmaceuticals
SizeMedium
TypePublic Company
ExchangeSWX
Websitedottikon.com
ISINCH0582581713
Last UpdateApr 2, 2026
Indices
SPI (Switzerland)
Themes
Environmental ConsultingCleanTechDisposal and RecyclingPollution ControlHealth CarePharmaceutical

Description

Dottikon ES Holding AG manufactures and sells performance chemicals, intermediates, and exclusive active pharmaceutical ingredients (APIs) for chemical, biotech, and pharmaceutical industries. Business Segments The company operates as a consolidate…

Analysis

Hope premium

Dottikon ES Holding AG carries what we call a hope premium: an average business trading at an ambitious price.

The price is expensive. You pay 78.4× its owner earnings: the cash an owner could take out each year, which is in the historically expensive zone.

The trajectory is moderate and the balance sheet is sturdy. The company scores 14/20 on our value-creation score: strong value creator.

What to watch: Some accounting patterns deserve a closer look. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
70
2023202420252026

All-time high

95

Jan 2023

All-time low

26

Feb 2026

Average rank

65

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
31
1
2
1
Price/Earnings
17
3
11
7
Price/Book
56
21
27
19
Dividend Yield
1
1
1
1
Value (overall)
25
1
1
1

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Dottikon with its peers
Novartis
VTX:NOVN
38
CountrySwitzerland
IndustryPharmaceuticals
SizeXX-Large
Full Stock Analysis →
GSK
LSE:GSK
72
CountryUK
IndustryPharmaceuticals
SizeXX-Large
Full Stock Analysis →
Avadel Pharmaceuticals
NMQ:AVDL
70
CountryIreland
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Virbac
PAR:VIRP
58
CountryFrance
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Cohance Lifesciences
NSI:COHANCE
37
CountryCyprus
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Sanofi India
NSI:SANOFI
56
CountryFrance
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →